A new survey from InCrowd found that 84% of surveyed physicians in dermatology, endocrinology, gastroenterology, oncology and rheumatology said they expect to prescribe, will prescribe or look forward to prescribing more biosimilars in the coming three years.
The companies said their biosimilar candidate, ABP 215, is the most advanced of the four oncologic biosimilars they are developing, and they believe it’s the first submission for an Avastin biosimilar.
The drug, which was approved in September, is indicated to treat adult and pediatric patients aged two years and over with primary immunodeficiency — a group of more than 300 genetic disorders that prevent the immune system from functioning properly.
Avella said that the acquisition would further its strategic vision to become the nation’s leading omni-site specialty pharmacy and add breadth to its compounding and oncology-focused capabilities and offerings.
Brill is board-certified in gastroenterology and internal medicine and is Predictive Health’s chief medical officer. He has formerly served as a medical director for several managed care organizations and has run independent practice organizations and physician-hospital organizations